An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Hemophilia B

Interventions

DRUG

BENEFIX

Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.

Trial Locations (2)

Peking Union Medical College Hospital, Beijing

Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing